Literature DB >> 29588773

The Bioresorbable Stent in Perspective-How Much of an Advance is It?

Viktor Kočka1, Petr Widimský1.   

Abstract

The novel idea of bioresorbable stent technology continues to fascinate the interventional community. This article aims to provide a concise and balanced overview of the available technology and clinical evidence. Both potentially positive and negative aspects of bioresorbable stents in different lesion subsets and clinical situations are discussed.

Keywords:  Bioresorbable vascular scaffold; biodegradable stent

Year:  2014        PMID： 29588773      PMCID： PMC5808682          DOI： 10.15420/icr.2011.9.1.23

Source DB:  PubMed          Journal:  Interv Cardiol        ISSN： 1756-1485


  31 in total

1.  Angiographic maximal luminal diameter and appropriate deployment of the everolimus-eluting bioresorbable vascular scaffold as assessed by optical coherence tomography: an ABSORB cohort B trial sub-study.

Authors:  Josep Gomez-Lara; Roberto Diletti; Salvatore Brugaletta; Yoshinobu Onuma; Vasim Farooq; Leif Thuesen; Dougal McClean; Jacques Koolen; John A Ormiston; Stefan Windecker; Robert Whitbourn; Dariusz Dudek; Cécile Dorange; Susan Veldhof; Richard Rapoza; Evelyn Regar; Hector M Garcia-Garcia; Patrick W Serruys
Journal:  EuroIntervention       Date:  2012-06-20       Impact factor: 6.534

2.  A comparison of the conformability of everolimus-eluting bioresorbable vascular scaffolds to metal platform coronary stents.

Authors:  Josep Gomez-Lara; Hector M Garcia-Garcia; Yoshinobu Onuma; Scot Garg; Evelyn Regar; Bernard De Bruyne; Stefan Windecker; Dougal McClean; Leif Thuesen; Dariusz Dudek; Jacques Koolen; Robert Whitbourn; Pieter C Smits; Bernard Chevalier; Cécile Dorange; Susan Veldhof; Marie-Angèle Morel; Ton de Vries; John A Ormiston; Patrick W Serruys
Journal:  JACC Cardiovasc Interv       Date:  2010-11       Impact factor: 11.195

3.  Four-year clinical follow-up of the ABSORB everolimus-eluting bioresorbable vascular scaffold in patients with de novo coronary artery disease: the ABSORB trial.

Authors:  Dariusz Dudek; Yoshinobu Onuma; John A Ormiston; Leif Thuesen; Karine Miquel-Hebert; Patrick W Serruys
Journal:  EuroIntervention       Date:  2012-01       Impact factor: 6.534

4.  ST elevation myocardial infarction treated with bioresorbable vascular scaffold: rationale and first cases.

Authors:  Viktor Kočka; Libor Lisa; Petr Toušek; Tomáš Buděšínský; Petr Widimský
Journal:  Eur Heart J       Date:  2013-05-31       Impact factor: 29.983

5.  Multislice computed tomography angiography for noninvasive assessment of the 18-month performance of a novel radiolucent bioresorbable vascular scaffolding device: the ABSORB trial (a clinical evaluation of the bioabsorbable everolimus eluting coronary stent system in the treatment of patients with de novo native coronary artery lesions).

Authors:  Koen Nieman; Patrick W Serruys; Yoshinobu Onuma; Robert-Jan van Geuns; Hector M Garcia-Garcia; Bernard de Bruyne; Leif Thuesen; Pieter C Smits; Jacques J Koolen; Dougal McClean; Bernard Chevalier; Ian Meredith; John Ormiston
Journal:  J Am Coll Cardiol       Date:  2013-08-07       Impact factor: 24.094

6.  Bioresorbable scaffold: the advent of a new era in percutaneous coronary and peripheral revascularization?

Authors:  Yosinobu Onuma; Patrick W Serruys
Journal:  Circulation       Date:  2011-02-22       Impact factor: 29.690

7.  "First-in-man" use of bioresorbable vascular scaffold in saphenous vein graft.

Authors:  Paul Jau Lueng Ong; Fahim Haider Jafary; Hee Hwa Ho
Journal:  EuroIntervention       Date:  2013-05-20       Impact factor: 6.534

8.  Long-Term (>10 Years) clinical outcomes of first-in-human biodegradable poly-l-lactic acid coronary stents: Igaki-Tamai stents.

Authors:  Soji Nishio; Kunihiko Kosuga; Keiji Igaki; Masaharu Okada; Eisho Kyo; Takafumi Tsuji; Eiji Takeuchi; Yasutaka Inuzuka; Shinsaku Takeda; Tatsuhiko Hata; Yuzo Takeuchi; Yoshitaka Kawada; Takeshi Harita; Junya Seki; Shunji Akamatsu; Shinichi Hasegawa; Nico Bruining; Salvatore Brugaletta; Sebastiaan de Winter; Takashi Muramatsu; Yoshinobu Onuma; Patrick W Serruys; Shigeru Ikeguchi
Journal:  Circulation       Date:  2012-04-16       Impact factor: 29.690

9.  Safety and performance of the drug-eluting absorbable metal scaffold (DREAMS) in patients with de-novo coronary lesions: 12 month results of the prospective, multicentre, first-in-man BIOSOLVE-I trial.

Authors:  Michael Haude; Raimund Erbel; Paul Erne; Stefan Verheye; Hubertus Degen; Dirk Böse; Paul Vermeersch; Inge Wijnbergen; Neil Weissman; Francesco Prati; Ron Waksman; Jacques Koolen
Journal:  Lancet       Date:  2013-03-09       Impact factor: 79.321

10.  Incidence and short-term clinical outcomes of small side branch occlusion after implantation of an everolimus-eluting bioresorbable vascular scaffold: an interim report of 435 patients in the ABSORB-EXTEND single-arm trial in comparison with an everolimus-eluting metallic stent in the SPIRIT first and II trials.

Authors:  Takashi Muramatsu; Yoshinobu Onuma; Hector M García-García; Vasim Farooq; Christos V Bourantas; Marie-Angèle Morel; Xiaolin Li; Susan Veldhof; Antonio Bartorelli; Robert Whitbourn; Alexandre Abizaid; Patrick W Serruys
Journal:  JACC Cardiovasc Interv       Date:  2013-03       Impact factor: 11.195
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.